Company intelligence / Profile preview

Elevai Research

Canada

Ownership: Private
Development stage: Other

Overview

Elevai Research's lead technology, PREx™, has demonstrated in partnership with Dalhousie University that its hUMSC-derived exosomes ("ELEVAI exosomes™") contain over 800 proteins related to wound healing, immunomodulation, and extracellular matrix remodeling, and are considerably more enriched for skin health proteins compared to reference datasets of other MSC-derived exosomes. Further in vitro studies and animal models are planned, and no clinical trials are yet reported for Elevai Research’s assets specifically.

Therapeutic areas: ImmunologyDermatologyRheumatology
Modalities: Exosome-based therapyRecombinant proteinBiologic
Industry: Biotech

Partnerships

Dalhousie University (Canada; protein profiling, R&D)

Beyond the preview

Go deeper on Elevai Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elevai Research.

Explore the full profile